Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the exclusive agreement, MS Pharma will be responsible for the registration and commercialization of FYB201/CHS-201 (Ranibizumab), in the Middle East and North African countries. MS Pharma will start the registration procedures in MENA immediately.
Lead Product(s): Ranibizumab
Therapeutic Area: Ophthalmology Product Name: CHS-201
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Polpharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 14, 2021